Session Abstract – PMWC 2022 Silicon Valley


  • Fireside Chat with Conrad Vial, Sutter Health and Precision Medicine Practices
    - Conrad Vial, Sutter Health
    - Erika Vial-Monteverdi, RotaCare Clinics
  • Precision Approaches to Chronic Disease
    Session Chair: Jennifer Lovejoy, Seven
    - Noel Mueller, Johns Hopkins
    - Maureen K. O'Connor, ZealCare
    - Sunjya K. Schweig, California Center For Functional Medicine (CCFM)
  • DNA-based Weight Loss Interventions: What Have We Learned?
    Session Chair: Jennifer Lovejoy, Seven
    - George Bray, Pennington Biomedical Research Center
    - Christopher Gardner, Stanford
  • A Scalable, Secure, and Interoperable Platform for Diabetes Detection and Management
    Session Chair: Mike Snyder, Stanford
    - Jessilyn Dunn, Duke University
    - Jonathan Long, Stanford
  • Illumina Accelerator Session
    Co-Chairs: Amanda Cashin, Illumina Accelerator & Marc Martin-Casas, Illumina Accelerator
    - Trevor Levin, Convergent
    - Rhidi Tariyal, NextGen Jane
    - Kareem Barghouti, VastBiome

 Session Chair Profile

Ph.D., Head of Science, Seven.me

Biography
Dr. Jennifer Lovejoy is a senior executive and biobehavioral scientist with deep experience in personalized medicine. During her academic career, Dr. Lovejoy held the Manship Endowed Professorship in Diabetes at LSU's Pennington Biomedical Research Center. She is a Past-President of the Obesity Society and has published over 80 peer-reviewed papers on her research. More recently, Dr. Lovejoy was Chief Translational Science Officer at Arivale, a precision medicine startup uniting systems biology and behavioral science to help consumers optimize wellness. Currently, she works at Seven.me, a digital health startup developing a unique behavioral AI platform combined with coaching and rapid at-home blood testing to help consumers transform their health.


 Session Chair Profile

Ph.D., Chair, Department of Genetics, Stanford University

Biography
Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and multiomics, and one of the major participants of the ENCODE project. His laboratory was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated (e.g. lncRNAs and TF binding sites), and a high diversity of transcription factor binding occurs both between and within species. He launched the field of personalized medicine by combining different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person, and his laboratory pioneered the use of wearables technologies (smart watches and continuous glucose monitoring) for precision health.


 Speaker Profile

Ph.D.,M.P.H., Assistant Professor, Johns Hopkins Bloomberg School of Public Health

Biography
I am a tenure-track Assistant Professor in the Department of Epidemiology at Johns Hopkins Bloomberg School of Public Health, a Core Faculty member in the Welch Center for Prevention, Epidemiology and Clinical Research. My research examines the nutritional, microbial, and environmental determinants of health across the lifespan, with the ultimate goal of identifying modifiable targets for chronic disease prevention and treatment. I believe that primary prevention of disease risk factors, in early life and among high-risk populations, provides the greatest opportunity to curb contemporary chronic disease epidemics and reduce health disparities. Accordingly, many of my investigations, in both local and global contexts, are in young, racially and ethnically diverse populations. A large part of my research focuses on the role of the human microbiome in nutrition and disease. I am particularly intrigued by the microbiome because it is amenable to intervention.

Talk
Sharpening Nutrition Science with the Microbiome
In this talk I will provide an overview of how the intestinal microbiota and their metabolites can inform more precise approaches to prevention and treatment of nutrition-related cardiometabolic diseases, including obesity, type 2 diabetes and obesity in both children and adults.


 Speaker Profile

M.D., Boyd Professor Emeritus, Pennington Biomedical Research Center

Biography
George A. Bray, M.D., founded the International Journal of Obesity in 1976, Chaired the 2nd International Congress on Obesity in 1977, founded the Obesity Society (NAASO) in 1981 and the journal Obesity in 1993. In 1989 he became the 1st Executive Director of the Pennington Biomedical Research Center. Among his many awards is the Presidential Medal from The Obesity Society and the 2019 Wilbur O Atwater Award from the USDA and ASN. Bray authored than 1,000 publications.

Talk
Lessons Learned from the POUNDS Lost Study
The POUNDS Lost study measured weight loss in 811 individuals assigned to 20% or 40% fat and 15% and 25% protein diets. Weight loss was not different between diet but there was a large variance. This study provides many lesson on interaction of diet with genetic and non-genetic factors.


 Speaker Profile

Ph.D., Rehnborg Farquhar Professor of Medicine, Stanford University

Biography
For ~30 years Christopher Gardner has studied what to consume and to avoid for optimal health, and how best to motivate individuals to achieve healthy dietary behaviors. Some of the dozens of human nutrition intervention trials he has conducted include studies of garlic, omega-3 fats, soy phytoestrogens and antioxidants. Among his most cited studies are the A TO Z (JAMA 2007) and the DIETFITS (JAMA 2018) weight loss diet trials. The DIETFITS trial examined the possibility that a 3-SNP multilocus genotype would predict differential weight loss success on a Healthy-Low-Fat vs. a Healthy-Low-Carb diet among more than 600 overweight and obese adults. His interests in this area of personalized nutrition continue with his participation in the Trans-NIH Consortium: Randomized Controlled Trials of Lifestyle Weight Loss Interventions for Genome-wide Association Studies. He is also working on personalized nutrition explorations with other investigators.

Talk
DNA-based Weight Loss Interventions: What Have We Learned?
The 2018 DIETFITS study tested the hypothesis that a 3-SNP genotype pattern would be an effect modifier of weight loss on a healthy low-fat vs. a healthy low-carb diet. The hypothesis was not supported. NIH convened a consortium too look at this question across studies. What have they learned?


 Speaker Profile

M.D., Founder and President, CCFM

Biography
Sunjya K. Schweig, MD, is Founder and President of the California Center for Functional Medicine (CCFM). CCFM provides personalized, precision medicine care that is fundamental for managing patients with chronic illness. CCFM integrates a comprehensive care team with cutting edge technology and data. This high-touch and high-tech approach offers patients the optimal opportunity for prevention and recovery from complex chronic illness. As a global leader in the functional medicine movement, since 2016 CCFM has been honored to run comprehensive wellness programs for first responders to help mitigate the unique occupational risks that they experience. A graduate of the University of California, Berkeley, Dr. Schweig completed his MD at the University of California, Irvine, and his family medicine residency at the University of California, San Francisco (UCSF), Family Practice Residency Program in Santa Rosa, CA. He is board certified in family practice (ABFM) and integrative and holistic medicine (ABIHM).


 Speaker Profile

J.D., CEO, ZealCare

Biography
Maureen O’Connor is a senior healthcare executive passionate about driving change in our health care system to improve lives. Currently, she served as CEO of ZealCare, an early stage health care services and technology company, spun out of Duke, with a mission to empower people with complex chronic conditions to live the life they want. The company provides intensive, individualized support to participants and their care team through personalized planning, education and virtual group visits. Initially, Zeal is targeting individuals with chronic kidney disease and type 2 diabetes. Formerly, Maureen served as president of Whiterabbit.ai, a Silicon Valley company with a mission to eradicate late-stage breast cancer through the use of artificial intelligence. Maureen spent 17 years as an executive with Blue Cross Blue Shield of North Carolina, serving as EVP of diversified businesses, president of Mosaic Health Solutions, and chief strategy and innovation officer.


 Speaker Profile

M.D., SVP, Chief Clinical Officer & Cardiothoracic Surgeon, Sutter Health

Biography
Dr. Vial is a practicing cardiac surgeon who also serves as the Chief Physician Executive of Operations for Sutter Health. In his leadership role, Dr Vial acts as a principal author of clinical strategy deployment, responsible for unifying clinical program building, business development, and operational efficiency across the continuum of care. An important focus of his work is the extension of ongoing specialty service line integration efforts, informing not only operations but also analytics and innovation through interdisciplinary clinical leadership platforms. From the clinical practice perspective, Dr. Vial is particularly interested in structural heart disease, focusing on minimally invasive cardiothoracic surgery and catheter-based valve repair/replacement. He received his bachelor’s degree and medical doctorate from Stanford University. In addition, Dr. Vial earned a master’s of philosophy at Cambridge University in England, while also completing a postdoctoral fellowship in transplant immunology. He received his general surgical and cardiothoracic surgical training at Stanford University Medical Center.

Talk
The Fusion of Healthcare Delivery and High Tech
When we say precision medicine, what is it that we are going to be precise about, and how does it help both patients and physicians? Tech thinks about users and providers think about patients. How can such differences be harnessed to learn from one another and work together to build and deploy effective precision medicine?


 Speaker Profile

M.B.A., Strategic Advisor, RotaCare Clinics

Biography
Erika is advises for-profit and non-profit healthcare start-up companies. She was the Executive Director of Cancer Commons, one of Silicon Valley’s only nonprofits focused on serving cancer patients globally through aligning incentives around the patient to produce better outcomes. Erika also helped spin out a for-profit health technology company, xCures, which uses artificial intelligence (A.I.) and predictive modeling to identify and rank the most promising treatment options for people with cancer who have exhausted the standard of care. She also serves as an Advisor to the for-profit company, StuffThatWorks.health, using smart, AI-based crowdsourcing to help people learn which treatments work best for their condition, and serves as Advisor to the Board of RotaryCare Free Clinics.

Talk
The Fusion of Healthcare Delivery and High Tech
When we say precision medicine, what is it that we are going to be precise about, and how does it help both patients and physicians? Tech thinks about users and providers think about patients. How can such differences be harnessed to learn from one another and work together to build and deploy effective precision medicine?


 Speaker Profile

Ph.D., Assistant Professor of Pathology, Stanford University

Biography
At Stanford, the Long laboratory studies the signaling pathways that control mammalian energy metabolism. Dr. Long’s contributions in the areas of metabolism and energy homeostasis have been recognized by numerous awards including the NIDDK DP1 Catalyst Award, the NIH Pathways to Independence Award, and the Ono Pharma Foundation Breakthrough Sciences Award. The long-term goal of this work is to discover new molecules and physiologic pathways that can be translated into therapeutic opportunities for obesity, metabolic disease, and other age-associated chronic diseases.


 Speaker Profile

Ph.D., Assistant Professor, Duke University

Biography
Jessilyn Dunn is the Director of the Duke BIG IDEAs Laboratory which is focused on biomedical data science and mobile health for digital biomarker discovery. Dr. Dunn is PI of the CovIdentify study to detect and monitor COVID-19 using mobile health technologies, which is built upon the team’s previous infection detection work through the DARPA Prometheus and Biochronicity programs. Dr. Dunn was an NIH Big Data to Knowledge (BD2K) Postdoctoral Fellow at Stanford, an NSF Graduate Research Fellow at Georgia Tech & Emory, and a visiting scholar at the CDC and the National Cardiovascular Research Institute in Madrid, Spain. Her work has been internationally recognized with media coverage from the NIH Director’s Blog to Wired, Time, and US News and World Report.